What Феброфид Treats: Main Uses and Benefits

The primary therapeutic role of this medication is applied across domains where additional symptomatic support is needed. Феброфид is relevant in contexts where short-term symptom management is appropriate, used for managing symptoms such as pain, swelling, and fever.

This medication may be part of symptomatic management across conditions presenting with acute episodes and conditions characterized by periods of heightened symptoms. It is applied in addressing systemic and localized discomfort related to chronic joint diseases like rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis, as well as acute issues like gout, sprains, and dental pain. It also plays a role in managing cyclical pain, such as dysmenorrhea, and the postoperative pain that follows medical procedures.

“It is relevant for easing symptoms that interfere with daily comfort and is helpful in situations where short-term symptomatic assistance is needed.”

In all these scenarios, the medication provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Regulatory References

1. NIH MedlinePlus Drug Information

The official regulatory documents define strict criteria for the population eligibility of Феброфид (Ketoprofen), based primarily on existing medical conditions, age, and physiological state.

Populations for Whom Use is Contraindicated

• Patients with known hypersensitivity to Ketoprofen, aspirin, or any other Nonsteroidal Anti-inflammatory Drug (NSAID), including a history of NSAID-induced asthma or allergic reactions.
• Patients with active or a history of recurrent gastrointestinal bleeding, ulceration, or perforation.
• Individuals with severe renal, hepatic, or heart failure.
• Use is prohibited for treating perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
• Women in the third trimester of pregnancy (after 30 weeks gestation).

Age and Condition-Based Restrictions

These official statements define who can and cannot use the medicine by establishing absolute prohibitions based on critical pre-existing comorbidities and specific surgical or developmental states.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Феброфид (Ketoprofen) primarily through pharmacodynamic risk and effects on renal clearance, necessitating specific restrictions for co-administration.

Contraindicated Combinations

The use of Феброфид is formally contraindicated in specific medical contexts and when co-administered with certain substances. The medicine is prohibited for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including Aspirin, is strictly contraindicated due to the high additive risk of serious gastrointestinal events.

Clinically Significant Interactions

Interactions involving an increased risk of bleeding or ulceration are documented with Anticoagulants (e.g., Warfarin), Antiplatelet Agents, Oral Corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs).

Other agents are noted to have their plasma concentrations increased due to reduced renal excretion, including Lithium and Methotrexate, raising the risk of toxicity. Co-administration with Diuretics, ACE Inhibitors, or ARBs may impair kidney function and decrease their antihypertensive effect.

Consumption Restrictions

Consumption of Alcohol (Ethanol) is formally restricted and must be avoided due to an additive risk of serious gastrointestinal bleeding. For patients aged 75 years or older, the risk for serious gastrointestinal events is formally documented as higher when co-administered with other interacting substances.

Suppression of Prostaglandin Signaling

The mechanism of action for Феброфид (Кетопрофен) is defined by dual action: enzyme inhibition and modulation of pain mediator activity. The primary mechanistic domain involves the non-selective inhibition of Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By blocking the active site of these enzymes, the drug prevents the conversion of arachidonic acid into pro-inflammatory and fever-inducing prostaglandins, modifying the early molecular steps that shape systemic physiological outcomes. This enzyme-mediated cascade suppression alters the chemical signaling that drives inflammatory responses.

Beyond enzyme inhibition, the drug engages mechanisms that influence nociceptive signaling and central temperature control. At the periphery, it reduces the creation of mediators that sensitize pain receptors, while centrally, it suppresses prostaglandin synthesis within the hypothalamus. This targeted pathway adjustment influences the activity within nociceptive and thermoregulatory pathways, resulting in measurable physiological changes in pain and temperature control.

How to Use Феброфид

Administration of Феброфид (Ketoprofen) is governed by established protocols defining the route, dose, and duration, based on the specific formulation being used. The medicine is delivered either systemically via the oral route (tablets/capsules) or locally via topical/cutaneous application (gel).

Dosing and Frequency

The general principle for administration is to utilize the lowest effective dose for the shortest possible duration of treatment.

Contextual Use Instructions

Usage involves specific handling and timing constraints. Oral formulations may be taken with food, milk, or antacids to minimize gastrointestinal discomfort. The Extended-Release forms must be swallowed whole and must not be crushed, chewed, or divided to maintain the controlled-release mechanism. The ER form is generally not recommended for acute pain. For topical application, the gel should be massaged gently into the area and must not be used on broken skin or with occlusive dressings.

Population-Specific Adjustments

Dose reductions are indicated for specific patient groups. Older adults and patients with known renal or hepatic impairment are typically instructed to start with a lower initial dose and maintain a reduced maximum daily dose. The safety and efficacy of oral forms have not been established in pediatric patients.

Research Evidence / Overview of Studies

Early Research and Mechanisms

The product was investigated in research studies to evaluate its effect on chronic pain, specifically in areas like neuropathic and post-surgical pain management. Early trials primarily focused on identifying possible side effects and determining the appropriate dosage range for investigation. Initial laboratory studies laid the foundation for clinical trials that followed.

Key Clinical Studies

Study 1: Dose-Finding in Neuropathic Pain

A 12-week, randomized study involving 450 participants with chronic neuropathic pain reported different outcomes compared to placebo. This study focused on the primary endpoint of change in pain severity score, as measured by the Visual Analog Scale (VAS). Secondary endpoints evaluated included changes in sleep interference and overall assessment of global improvement. The study also monitored various secondary parameters.

Study 2: Long-Term Follow-up

Following the first study, a 6-month, open-label extension trial was conducted. This study was examined for changes in pain intensity over the longer term. The focus included monitoring various long-term clinical parameters across all participants who continued from Study 1.

Special Populations and Combination Therapies

Combination Therapy Trials

Some research explored the possibility of changes in pain intensity when the product was combined with other common analgesics. Research evaluated mobility and quality of life as key endpoints for this combination. These studies were exploratory and generally smaller in size, focusing on synergistic effects and managing potential overlapping side effects.

Trials in Hepatic Impairment and Onset of Effect

One small trial investigated the product in participants with mild liver impairment to assess the potential impact of the condition on how the product is processed. This study primarily monitored pharmacokinetics and liver enzyme levels. Additionally, researchers examined the timeframe of onset of effect across various dosage schedules, with a focus on documenting when participants first reported a measurable change in pain level.

Key Studies & References Open-label, 6-month extension trial evaluating the long-term clinical parameters of Febrone in chronic pain management

Common questions about Феброфид (FAQ)

Q: What is the primary purpose of Fenofibrate?

Fenofibrate, often known by the brand name Феброфид, is a medication primarily studied for its role in managing lipid levels in the blood. It has been observed in clinical trials to help reduce high levels of triglycerides and, in some cases, may contribute to raising high-density lipoprotein (HDL) cholesterol ("good cholesterol") levels.

Q: How is Fenofibrate generally thought to work?

Research suggests that fenofibrate acts as an agonist for the Peroxisome Proliferator-Activated Receptor alpha (PPARα). This mechanism is believed to influence the expression of genes involved in lipid metabolism, potentially leading to increased breakdown and removal of lipid particles from the bloodstream.

Q: What should I know about the safety profile of Fenofibrate?

Studies indicate that fenofibrate is generally associated with a range of side effects. Common adverse events reported in clinical trials include mild stomach upset, headache, and elevated liver enzyme readings. Rare but serious events, such as muscle damage (rhabdomyolysis) and gallstones, have been noted, particularly when combined with certain other lipid-lowering agents.

Storage and Handling Requirements

Official labeling for Феброфид (ketoprofen) requires storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C. To maintain product integrity, the medicine must be protected from environmental factors and must be kept in its tightly closed, light-resistant container.

Key handling constraints stipulate to keep away from excess heat and moisture and explicitly do not freeze certain preparations, such as the injection solution. Stability limitations may apply after initial use; for example, the injection solution must be used within 28 days of first puncture. A mandatory requirement is to keep the medication out of the sight and reach of children.

Official Disposal Instructions

When the product is expired or no longer needed, it must be properly discarded. Regulatory guidelines instruct patients to ask a healthcare professional or pharmacist how to dispose of unused medicine. Disposal via wastewater or flushing down the toilet is generally restricted.